Shares of PI Industries were down 8 per cent to Rs 2,756 on the BSE in Tuesday’s intra-day trade after the company terminated the agreement related to acquisition on slump sale of Ind-Swift Laboratories (ISLL). This is due to ISLL has not been able to complete several of the pre-agreed conditions precedents.

“Given non-fulfilment and also disagreement on some of the pre-agreed conditions, the company has decided not to pursue the transaction further,” PI Industries said in a statement.

• Orient Cables Eyes Rs 3,500 Crore Revenue By FY30
• Bangladesh Resumes Indian Wheat Purchases as Black Sea Disruptions Lift Prices
• Central Railway Recovers Rs 140 Crore In Ticket Fines
• Cosmic CRF Unit Bags Rs 25.94 Crore Combined Orders
• Arivihan in Talks to Raise Rs 96 Crore at Rs 570 Crore Valuation

PIs’ strategy to strengthen presence in custom synthesis exports through diversification into adjacencies, including pharma, remains intact. The R&D establishment within PI remains attuned to developing and scaling multiple advanced technologies, processes, and platforms to execute its long-term strategy, the company said. “PI Industries will continue to evaluate other M&A opportunities that are aligned to it strategic direction with the intention to create a differentiated scale play in pharma,” it added.